SCHEMBL4875231

SCHEMBL4875231

CC(C)(C)[Si](C)(C)Oc1cccc([C@@H]2CCN(C(=O)O)C[C@H]2O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
HTT P42858 1/20 0.38
JAK2 O60674 1/20 0.36
JAK3 P52333 1/20 0.36
PTK2 Q05397 1/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
BCL9 O00512 6/20 0.35
CTNNB1 P35222 6/20 0.35
PPARA Q07869 3/20 0.34
PPARG P37231 2/20 0.34
CHRM4 P08173 1/20 0.34
SLC18A3 Q16572 1/20 0.34
EPHX2 P34913 2/20 0.34
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14256143 0.89 JAK2 (0.46) HSP90AA1HSP90AB1JAK2JAK3PTK2
SCHEMBL4864580 0.80 SCN1A (0.39) HSP90AA1HSP90AB1BCL9CTNNB1PPARA
SCHEMBL6042159 0.77 HRH3 (0.46) HTTTP53SLC18A3
SCHEMBL6042250 0.75 SLC18A3 (0.55) HTTNPC1TP53MAPTRAB9A
SCHEMBL2241229 0.75 SLC18A3 (0.55) HTTNPC1TP53MAPTRAB9A
SCHEMBL2241225 0.75 SLC18A3 (0.55) HTTNPC1TP53MAPTRAB9A
SCHEMBL18585650 0.74 HSD11B1 (0.46) HTTKMT2ANPC1TP53MAPT
SCHEMBL6041802 0.74 NPC1 (0.46) HTTNPC1RAB9ACHRM4SLC18A3
SCHEMBL4351851 0.74 HTT (0.44) HTTNPC1TP53RAB9ASMN1; SMN2
SCHEMBL6042542 0.74 HTT (0.43) HTTKMT2AEPHX2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7338965-B2 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines PHARMACIA & UPJOHN COMPANY (US) 2008-03-04 US disclosed
EP-1448200-A2 (4-PHENYL)PIPERIDIN-3-YL-PHENYLCARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-08-25 EP disclosed
US-20040034031-A1 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines ELAN PHARMACEUTICALS, INC. 2004-02-19 US disclosed
WO-2003043987-A2 (4-PHENYL) PIPERIDIN-3-YL-PHENYLCARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034031-A1 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines BACE1, APP, BACE2 HSP90AA1 2133/4885HSP90AB1 1424/4885HTT 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.